Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Otosporin is a fixed-dose combination ear drop containing the corticosteroid hydrocortisone and the antibiotics neomycin and polymyxin B. It is approved for the treatment of bacterial otitis externa (swimmer's ear) and other superficial bacterial infections of the external auditory canal. Hydrocortisone acts as an anti-inflammatory agent by agonizing the glucocorticoid receptor, thereby reducing swelling, redness, and itching. Neomycin, an aminoglycoside, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while polymyxin B, a polypeptide antibiotic, disrupts the bacterial outer membrane by binding to lipopolysaccharides (specifically lipid A). Together, these components provide comprehensive antibacterial and anti-inflammatory action to resolve ear infections and alleviate associated discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Otosporin.